Create Free Account

By creating account you will get access to hot stocks & personalised emails

MGC Pharmaceuticals Ltd

Healthcare AU MXC

0.415AUD
-(-%)

Last update at 2024-04-29T00:00:00Z

Day Range

0.410.42
LowHigh

52 Week Range

0.309.00
LowHigh

Fundamentals

  • Previous Close 0.41
  • Market Cap18.42M
  • Volume6035
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.44245M
  • Revenue TTM1.32M
  • Revenue Per Share TTM0.10
  • Gross Profit TTM 1.29M
  • Diluted EPS TTM-3.21

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -21.13152M -17.13873M -13.53175M -18.81432M -1.87636M
Minority interest 0.31M 0.37M -0.00865M -0.01097M -0.16116M
Net income -20.82358M -16.76576M -13.96511M -19.36309M -1.90367M
Selling general administrative 12.49M 8.28M 5.73M 6.61M 2.61M
Selling and marketing expenses 0.93M 0.95M 0.58M 0.56M 0.57M
Gross profit 1.45M 1.63M 1.31M 0.13M 0.30M
Reconciled depreciation 0.49M 0.50M 0.49M 0.48M 0.26M
Ebit -15.99332M -14.62628M -12.48741M -9.49769M 0.62M
Ebitda -15.49959M -14.12199M -11.99600M -9.01656M 0.88M
Depreciation and amortization 0.49M 0.50M 0.49M 0.48M 0.26M
Non operating income net other - - - - -
Operating income -15.23443M -15.49923M -11.93868M -11.28579M 0.62M
Other operating expenses -20.05971M -16.95171M -14.74108M -16.91671M 9.70M
Interest expense 0.34M 0.19M 0.37M 0.14M 0.00800M
Tax provision 0.00202M 0.00000M -0.02728M 0.00000M 0.03M
Interest income 0.34M 0.00030M 0.36M 0.01M 0.20M
Net interest income -0.33701M -0.18975M -0.36150M -0.12325M 0.19M
Extraordinary items - - -0.46264M -0.60043M 2.43M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00202M -1.35950M -0.02728M 1.21M 0.03M
Total revenue 3.39M 4.65M 2.96M 2.03M 0.66M
Total operating expenses 17.15M 15.08M 13.38M 12.55M 9.34M
Cost of revenue 1.94M 3.01M 1.65M 1.90M 0.36M
Total other income expense net -5.09725M -3.49897M -1.10033M -8.65673M -2.49743M
Discontinued operations - - -0.46264M -0.60043M 2.43M
Net income from continuing ops -21.13353M -17.13873M -13.50447M -18.81432M -1.90367M
Net income applicable to common shares -20.82358M -16.76576M -15.86998M -19.36309M -8.57933M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 9.88M 18.56M 24.24M 7.93M 13.00M
Intangible assets 0.00000M 5.38M 7.05M 0.00000M 5.03M
Earning assets - - - - -
Other current assets 0.40M -0.90063M 0.83M 0.43M 0.09M
Total liab 18.02M 13.38M 10.41M 4.83M 2.20M
Total stockholder equity -7.50606M 5.74M 13.83M 3.11M 10.96M
Deferred long term liab - - - - -
Other current liab 10.30M 3.67M 4.29M 0.11M 0.37M
Common stock 103.71M 97.44M 77.75M 60.15M 49.13M
Capital stock 103.71M 97.44M 84.51M 60.15M 49.13M
Retained earnings -119.16892M -94.76365M -76.09302M -62.12792M -41.46483M
Other liab 4.30M 2.38M 2.51M 0.02M 0.02M
Good will - 5.38M 7.05M 7.05M -
Other assets 0.00000M 0.16M 0.56M - -
Cash 0.24M 1.79M 5.43M 1.87M 2.35M
Cash and equivalents - - - - 2.35M
Total current liabilities 13.26M 7.71M 6.13M 2.97M 2.18M
Current deferred revenue 0.58M 1.38M -4.28168M 0.10M 0.59M
Net debt 0.34M 0.51M 1.24M 0.03M -0.45486M
Short term debt 0.19M 0.15M 4.90M 0.05M 0.05M
Short long term debt - 2.10M 4.69M - -
Short long term debt total 0.58M 2.29M 6.67M 1.90M 1.90M
Other stockholder equity 0.21M -5.87619M -6.51409M 5.08M 4.59M
Property plant equipment 7.45M 9.70M 7.14M 4.02M 1.47M
Total current assets 2.43M 6.46M 9.48M 3.23M 3.72M
Long term investments - 0.16M - 0.67M 2.77M
Net tangible assets -7.40308M 6.23M 6.79M 3.11M 5.93M
Short term investments - - - - -
Net receivables 0.53M 3.35M 2.35M 0.41M 1.14M
Long term debt - - 0.00000M 0.00000M 0.00000M
Inventory 1.26M 2.22M 0.87M 0.40M 0.14M
Accounts payable 2.19M 2.50M 1.22M 2.71M 1.16M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.95M 8.94M 7.32M 5.08M 3.29M
Additional paid in capital - - - - -
Common stock total equity - - - 60.15M 49.13M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.16M 0.56M 0.56M 2.77M
Deferred long term asset charges - - - - -
Non current assets total 7.45M 12.10M 14.75M 4.70M 9.28M
Capital lease obligations 0.58M 2.29M 1.98M 1.90M -
Long term debt total 0.38M 2.14M 1.77M 1.85M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.05M -2.44329M 0.30M -0.96988M -0.94703M
Change to liabilities 0.19M 1.63M -0.81997M 0.52M 0.63M
Total cashflows from investing activities 0.61M -2.44329M -1.49378M -0.96988M -0.94703M
Net borrowings 6.96M -0.26301M 5.49M -0.18361M -0.18361M
Total cash from financing activities 9.31M 9.74M 16.68M 10.65M 0.03M
Change to operating activities - - - - -
Net income -20.82358M -20.34744M -15.86998M -19.36309M -2.30933M
Change in cash -1.64653M -3.66475M 3.56M -0.48071M -7.50489M
Begin period cash flow 1.89M 5.43M 1.87M 2.35M 9.86M
End period cash flow 0.24M 1.77M 5.43M 1.87M 2.35M
Total cash from operating activities -11.98517M -12.15822M -11.98961M -9.95687M -6.35421M
Issuance of capital stock 2.70M 10.76M 12.76M 11.43M 0.04M
Depreciation 0.75M 0.14M 0.49M 0.48M 0.26M
Other cashflows from investing activities 0.80M 1.58M 2.45M -0.01325M -0.56999M
Dividends paid -0.21634M -0.06142M 0.06M - -
Change to inventory 0.48M -0.96536M -0.47021M -0.26344M 0.57M
Change to account receivables 1.41M 1.29M -2.22031M 0.27M -0.29497M
Sale purchase of stock -0.08143M -0.76406M -1.20265M -0.78768M -0.00895M
Other cashflows from financing activities 7.13M -0.14016M 5.12M -0.96988M -0.94703M
Change to netincome 6.02M 5.94M 6.90M 8.40M 1.05M
Capital expenditures 0.74M 4.02M 3.33M 0.96M 0.36M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.88M 0.33M -2.69052M 0.00847M -2.40629M
Stock based compensation 2.66M 0.64M 1.65M 0.85M -
Other non cash items 8.09M 8.05M 3.39M 8.93M 2.05M
Free cash flow -12.72385M -16.17609M -15.31672M -10.91896M -6.71636M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MXC
MGC Pharmaceuticals Ltd		 - -% 0.41 - 14.90 13.91 13.86 7.66 -0.8303
AFP
AFT Pharmaceuticals Ltd		 -0.04 1.37% 2.89 21.54 17.06 1.79 4.41 2.18 16.66
VLS
Vita Life Sciences Ltd		 - -% 2.25 13.24 - 1.73 2.97 1.41 7.98
NXS
Next Science Ltd		 -0.01 3.45% 0.28 - 128.21 4.47 5.03 3.90 -5.9908
PER
Percheron Therapeutics Limited		 0.002 2.70% 0.08 - - 31.54 4.38 347.00 -4.319

Reports Covered

Stock Research & News

View All

Profile

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

MGC Pharmaceuticals Ltd

295 Rokeby Road, Subiaco, WA, Australia, 6008

Key Executives

Name Title Year Born
Mr. Roby Reuven Zomer Co-Founder, CEO, MD & Exec. Director 1980
Ms. Angela-Marie Graham Group Chief Financial Officer NA
Ms. Yifat Steuer Deputy CEO & COO NA
Mr. Amir Polak Chief Technology Officer NA
Ms. Nicole Ann Godresse Global Chief Sales Officer NA
Ms. Sabina Suljakovic Head of the Quality Assurance Department NA
Dr. Nadya Lisovoder Chief Medical Officer NA
Ms. Sasha Friedman Deputy CEO NA
Yair Tal Chief Information Security Officer NA
Mr. Robert Clements Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.